Pr. Jean-François Chatal
Jean-François is a Distinguished Professor of Nuclear Medicine at the University of Nantes, France. He is currently in charge of the Medical Affairs of ARRONAX Cyclotron. Over the past, he directed the Nuclear Medicine Department of University Hospital and Cancer Centre. He created and headed over more than two decades an INSERM (National Institute of Health and Medical Research) research team devoted to diagnostic and therapeutic use of radiolabeled monoclonal antibodies in oncology. Jean-François is co-initiator of the project termed ARRONAX, a high energy/high intensity cyclotron located in metropolitan area of Nantes, for the production of innovative radionuclides for diagnostic and therapeutic Nuclear Medicine research in Europe.
Dr. Jacques Barbet
Jacques is the Director of the ARRONAX Cyclotron. He is graduated Engineer from Ecole Polytechnique in Paris and received his PhD in organic chemistry in 1978. He moved to the CIML Immunology Center in Marseilles where he specialized in antibodies, drug targeting and anti-cancer drug pharmacokinetics. In the nineties, he headed the Imaging and Therapeutics Department of Immunotech (Marseilles) where he developed the Affinity Enhancement System, a pretargeting approach, which is under development in the clinic for cancer radioimmunotherapy. In 2001, he joined the INSERM research team in Nantes that focuses on radioimmunotherapy and alpha-immunotherapy. With Jean-Francois Chatal, Jacques Martino and Yves Thomas, he is one of the scientists who launched the ARRONAX project.
Pr. Alain Faivre Chauvet
Alain is a University Biophysics Professor and Radiopharmacist at the University Hospital of Nantes. He is graduated Pharmacist from the Faculty of Pharmacy Paris V and he joined in 1990, the INSERM research team in Nantes working on the development of innovative radiopharmaceuticals working with a broad range of radionuclides suitable for clinical applications. Since 2000, He heads the Radiopharmacy unit of Nantes. He is involved at national and international level to the development of this specialty as President of the National Radiopharmacy Society and as Delegate of the EANM Radiopharmacy committee (European Association of Nuclear Medicine).